Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.
Pignata S, Amant F, Scambia G, Sorio R, Breda E, Rasch W, Hernes K, Pisano C, Leunen K, Lorusso D, Cannella L, Vergote I. Pignata S, et al. Among authors: rasch w. Cancer Chemother Pharmacol. 2011 Nov;68(5):1347-53. doi: 10.1007/s00280-011-1735-4. Epub 2011 Sep 10. Cancer Chemother Pharmacol. 2011. PMID: 21909644 Clinical Trial.
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM. Brunsvig PF, et al. Among authors: rasch w. Front Immunol. 2020 Nov 26;11:572172. doi: 10.3389/fimmu.2020.572172. eCollection 2020. Front Immunol. 2020. PMID: 33324397 Free PMC article. Clinical Trial.
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G. Aamdal E, et al. Among authors: rasch w. Front Immunol. 2021 May 11;12:663865. doi: 10.3389/fimmu.2021.663865. eCollection 2021. Front Immunol. 2021. PMID: 34046035 Free PMC article. Clinical Trial.
Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile.
Knapper S, Chevassut T, Duarte R, Bergua JM, Salamero O, Johansen M, Jacobsen TF, Hals PA, Rasch W, Gianella-Borradori A, Smith M. Knapper S, et al. Among authors: rasch w. Leuk Res. 2014 Mar;38(3):346-51. doi: 10.1016/j.leukres.2013.12.011. Epub 2013 Dec 25. Leuk Res. 2014. PMID: 24433865 Clinical Trial.
41 results